BEX2 is required for maintaining dormant cancer stem cell in hepatocellular carcinoma.
Aged
Aldehyde Dehydrogenase
/ metabolism
Animals
Antineoplastic Agents
/ pharmacology
Carcinoma, Hepatocellular
/ drug therapy
Cell Line, Tumor
Cholangiocarcinoma
/ metabolism
Cisplatin
/ pharmacology
Female
Gene Silencing
Humans
Liver Neoplasms
/ drug therapy
Male
Mice
Neoplastic Stem Cells
/ metabolism
Nerve Tissue Proteins
/ genetics
Organoids
Prognosis
Spheroids, Cellular
BEX2
cancer stem cell
dormant
hepatocellular carcinoma
prognosis
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
12
08
2021
received:
08
04
2021
accepted:
21
08
2021
pubmed:
24
8
2021
medline:
24
11
2021
entrez:
23
8
2021
Statut:
ppublish
Résumé
Cancer stem cells (CSCs) are responsible for therapy resistance and share several properties with normal stem cells. Here, we show that brain-expressed X-linked gene 2 (BEX2), which is essential for dormant CSCs in cholangiocarcinoma, is highly expressed in human hepatocellular carcinoma (HCC) lesions compared with the adjacent normal lesions and that in 41 HCC cases the BEX2
Identifiants
pubmed: 34424582
doi: 10.1111/cas.15115
pmc: PMC8586677
doi:
Substances chimiques
Antineoplastic Agents
0
BEX2 protein, human
0
Nerve Tissue Proteins
0
Aldehyde Dehydrogenase
EC 1.2.1.3
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4580-4592Subventions
Organisme : JSPS KAKENHI
ID : 19K08430
Organisme : JSPS KAKENHI
ID : 19K17416
Organisme : JSPS KAKENHI
ID : 18K15799
Organisme : JSPS KAKENHI
ID : 17K10716
Organisme : JSPS KAKENHI
ID : 16K07132
Organisme : JSPS KAKENHI
ID : 20K17068
Organisme : JSPS KAKENHI
ID : 20H03756
Organisme : Practical Research for Innovative Cancer Control from AMED
ID : JP17ck0106197
Organisme : Takeda Medical Foundation
Informations de copyright
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Oncotarget. 2015 Dec 29;6(42):44191-206
pubmed: 26496035
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Nucleic Acids Res. 2005 Nov 24;33(20):6555-65
pubmed: 16314316
Cancer Sci. 2010 Oct;101(10):2145-55
pubmed: 20707805
J Clin Invest. 2010 Sep;120(9):3326-39
pubmed: 20697159
Cell Stem Cell. 2011 Jul 8;9(1):50-63
pubmed: 21726833
Tumour Biol. 2017 Mar;39(3):1010428317692248
pubmed: 28345458
Hum Mol Genet. 1999 Apr;8(4):611-9
pubmed: 10072429
Breast Cancer Res. 2016 May 24;18(1):55
pubmed: 27220421
Mol Cancer. 2010 May 19;9:111
pubmed: 20482821
Science. 1985 Jun 14;228(4705):1321-4
pubmed: 2408339
Cancer Cell. 2008 Feb;13(2):153-66
pubmed: 18242515
J Exp Med. 2011 Dec 19;208(13):2641-55
pubmed: 22124112
Sci Rep. 2016 Jul 29;6:30707
pubmed: 27469492
J Mol Neurosci. 2013 May;50(1):78-87
pubmed: 22907646
Biochem Biophys Res Commun. 2012 Oct 26;427(3):574-80
pubmed: 23022184
Cancer Lett. 2019 Oct 1;461:144-152
pubmed: 31325530
Cancer Res. 2018 Nov 15;78(22):6424-6435
pubmed: 30224376
J Biol Chem. 2014 Oct 24;289(43):29892-911
pubmed: 25143383
Cancer Sci. 2021 Nov;112(11):4580-4592
pubmed: 34424582
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Int J Biol Sci. 2017 Feb 12;13(3):286-294
pubmed: 28367093
Lab Invest. 2019 Sep;99(9):1349-1362
pubmed: 31019292
Cancer Cell. 2012 Mar 20;21(3):283-96
pubmed: 22439924
Genome Biol. 2013 Apr 17;14(4):R31
pubmed: 23594475
Sci Rep. 2020 Dec 9;10(1):21592
pubmed: 33299012